Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Grand Pharmaceutical Group stock

512.HK
BMG210A71016
A0Q8LD

Price

4.80 HKD
Today +/-
+0.01 HKD
Today %
+1.26 %

Grand Pharmaceutical Group stock price

HKD
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Grand Pharmaceutical Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Grand Pharmaceutical Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Grand Pharmaceutical Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Grand Pharmaceutical Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Grand Pharmaceutical Group Stock Price History

DateGrand Pharmaceutical Group Price
2/21/20254.80 HKD
2/20/20254.74 HKD
2/19/20254.63 HKD
2/18/20254.72 HKD
2/17/20254.64 HKD
2/14/20254.59 HKD
2/13/20254.44 HKD
2/12/20254.48 HKD
2/11/20254.39 HKD
2/10/20254.45 HKD
2/7/20254.36 HKD
2/6/20254.38 HKD
2/5/20254.26 HKD
2/4/20254.22 HKD
2/3/20254.26 HKD
1/28/20254.22 HKD
1/27/20254.39 HKD

Grand Pharmaceutical Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Grand Pharmaceutical Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Grand Pharmaceutical Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Grand Pharmaceutical Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Grand Pharmaceutical Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Grand Pharmaceutical Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Grand Pharmaceutical Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Grand Pharmaceutical Group’s growth potential.

Grand Pharmaceutical Group Revenue, EBIT and net profit per share

DateGrand Pharmaceutical Group RevenueGrand Pharmaceutical Group EBITGrand Pharmaceutical Group Net Income
2030e14.24 B HKD0 HKD0 HKD
2029e14.11 B HKD2.69 B HKD0 HKD
2028e13.65 B HKD2.76 B HKD0 HKD
2027e13.11 B HKD2.81 B HKD0 HKD
2026e15.59 B HKD3.21 B HKD2.54 B HKD
2025e14.16 B HKD2.87 B HKD2.23 B HKD
2024e12.57 B HKD2.65 B HKD1.97 B HKD
202310.53 B HKD2.86 B HKD1.88 B HKD
20229.56 B HKD2.75 B HKD2.08 B HKD
20218.6 B HKD2.18 B HKD2.4 B HKD
20206.35 B HKD1.78 B HKD1.79 B HKD
20196.59 B HKD1.34 B HKD1.15 B HKD
20185.96 B HKD961.09 M HKD712.67 M HKD
20174.77 B HKD692.94 M HKD460.81 M HKD
20163.7 B HKD457.04 M HKD269.14 M HKD
20153.25 B HKD354.39 M HKD180.91 M HKD
20143.12 B HKD298.7 M HKD175.21 M HKD
20132.66 B HKD188.8 M HKD99.7 M HKD
20122.06 B HKD147.3 M HKD67.3 M HKD
20111.65 B HKD116.2 M HKD54.2 M HKD
20101.05 B HKD179.9 M HKD98 M HKD
2009545.4 M HKD52.8 M HKD28.3 M HKD
2008269.9 M HKD-2.1 M HKD-24.2 M HKD
200749 M HKD-45.5 M HKD-52 M HKD
200642.4 M HKD-6.8 M HKD-10.7 M HKD
200546.4 M HKD-102.3 M HKD-97.2 M HKD
200463.2 M HKD-140.4 M HKD-130.2 M HKD

Grand Pharmaceutical Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B HKD)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B HKD)NET INCOME (B HKD)NET INCOME GROWTH (%)DIV. (HKD)DIV. GROWTH (%)SHARES (B)DOCUMENTS
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0.190.160.160.130.080.070.060.050.040.050.270.551.051.652.062.663.123.253.74.775.966.596.358.69.5610.5312.5714.1615.5913.1113.6514.1114.24
--18.320.64-19.11-37.01-17.50-4.55-26.98-8.7016.67448.98102.6093.3956.2625.0229.0917.463.9413.9029.0624.9110.61-3.6135.3411.2210.1119.3812.6610.08-15.914.123.350.92
50.7956.4160.5162.9958.7556.0631.7543.4845.2444.9040.5245.8735.4831.2731.3333.3338.2141.6046.8651.9753.0561.3263.5261.0362.2461.9651.9046.0741.8549.7747.8046.2545.83
0.10.090.10.080.050.040.020.020.020.020.110.250.370.520.650.891.191.351.732.483.164.044.045.255.956.520000000
-0.04-0.02-0.12-0.16-0.03-0.09-0.13-0.1-0.01-0.05-0.020.030.10.050.070.10.180.180.270.460.711.151.792.42.081.881.972.232.540000
--33.33387.5032.48-80.65193.3347.73-25.38-89.69420.00-53.85-216.67250.00-44.9024.0747.7676.772.8649.4471.0054.7861.5255.8334.04-13.45-9.575.0012.9214.13----
---------------------------------
---------------------------------
0.040.040.040.040.040.060.370.971.121.121.121.321.511.931.961.972.022.222.322.52.793.373.453.553.543.510000000
---------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Grand Pharmaceutical Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Grand Pharmaceutical Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B HKD)RECEIVABLES (B HKD)OTHER REC. (B HKD)INVENTORIES (B HKD)OTHER CURRENT LIAB. (M HKD)CURRENT ASSETS (B HKD)TANGIBLE ASSETS (B HKD)LONG-T. INVEST. (B HKD)LONG-T. REC. (M HKD)INTANGIBLE ASSETS (B HKD)GOODWILL (M HKD)OTHER NON-CURRENT ASSETS (B HKD)NON-CURRENT ASSETS (B HKD)TOTAL ASSETS (B HKD)LIABILITIESCOMMON STOCK (M HKD)ADDITIONAL PAID-IN CAPITAL (B HKD)RETAINED EARNINGS (B HKD)OTHER EQUITY (M HKD)UNREAL. GAINS/LOSSES (M HKD)EQUITY (B HKD)LIABILITIES (B HKD)PROVISIONS (B HKD)OTHER SHORT-TERM LIAB. (M HKD)SHORT-TERM DEBTS (M HKD)LONG-TERM DEBT PORTION (B HKD)SHORT-TERM REC. (B HKD)LONG-T. LIAB. (B HKD)DEFERRED TAXES (M HKD)OTHER LIAB. (M HKD)LONG-T. LIABILITIES (B HKD)DEBT (B HKD)TOTAL CAPITAL (B HKD)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                   
0.240.240.110.130.110.090.090.060.070.070.040.060.310.340.310.250.510.660.50.660.961.132.362.872.482.47
0.050.050.050.020.020.020.010.010.010.010.060.080.140.20.210.320.350.470.70.910.930.90.820.971.090.96
000000000-00.010.010.110.150.250.60.660.620.610.440.430.660.91.181.111.37
0.030.020.020.010.010.010000.010.060.060.220.320.440.560.520.620.640.760.770.810.961.121.341.39
252673141000140106597634134100.7746.6139.18177.96339.23316.05290.07646.17856.94829.05
0.340.330.240.180.140.120.10.070.10.080.180.210.831.091.241.872.132.412.482.953.433.825.326.786.897.02
0.330.310.280.190.20.150.090.030.030.040.130.140.450.731.422.112.292.542.642.892.883.263.413.83.943.99
0.0100.010.010.010.010.010.080.080.080.060.070.040.060.060.050.050.320.370.445.485.346.448.388.458.4
0000000000000173720014.410000113.96000
00000.060.130.070.010.010000000.080.070.650.80.880.820.790.881.011.41.66
000000021000557297125124.68380.59481.08511.54487.85480.32505.57596.75644.05588.62
0.010.020.0100000000.20.20.310.470.490.310.30.320.370.40.410.120.320.491.050.87
0.350.330.30.20.260.30.170.130.130.110.390.40.861.342.112.692.844.234.665.1210.071011.6714.2815.4815.5
0.680.670.540.380.390.410.270.20.220.20.570.611.692.433.354.574.976.637.148.0613.513.8116.9821.0622.3722.52
                                                   
8282828298138411111111111919202019.6219.6222.3722.3731.3533.7835.535.535.535.5
00.210.210.210.220.220.030.090.090.090.090.090.270.270.280.280.280.280.660.665.055.516.526.526.526.52
0.40.240.12-0.03-0.06-0.150.08-0.02-0.03-0.08-0.1-0.070.260.310.40.50.680.791.041.472.183.044.516.538.229.61
0-71-70-70-70-70-70-69-69-690018374674135.0470.78-24.3181.92-75.94-207.89163.04439.96-355.3-459.77
000000000000633000000.861.0411.873.05-98.97-279.17
0.480.460.340.190.190.140.040.020.01-0.040.010.030.570.640.750.881.111.161.72.237.198.3811.2413.5414.3315.43
0.020.030.060.060.040.040.030.05000.080.060.140.150.310.710.660.650.70.631.060.830.660.730.871.33
000000000.050.050.060.080.160.160.310.60.470.530.660.941.291.191.482.141.621.5
10610668606060647000283535364049.5160.7481.26214.86318.14573.14528.92565.01688.56530.24
0000182510221400000012.46000284.73059.917.162518.91
0.040.040.050.050.050.050.10.040.050.090.080.120.310.71.311.271.092.011.712.222.020.991.572.123.252.35
0.170.180.180.180.150.160.220.170.130.160.220.260.641.031.962.612.273.253.164.014.973.594.35.576.455.73
000000.0800000.20.150.040.040.120.40.671.181.210.770.321.070.811.521.221.05
000000022045436883815058.98143.88189.08195.58179.01171.51181.88197.85220.15221.63
0000231007581202296311321406682.88657.4608.75632.25595.89466.61341.61326.82265.28240.11
00000.030.08000.080.080.260.220.20.430.520.861.411.982.011.61.11.711.342.051.711.51
0.170.180.180.180.180.240.220.170.210.240.480.480.841.462.483.473.685.235.175.66.065.35.647.618.167.24
0.660.640.520.370.370.380.260.190.220.20.490.511.412.13.234.354.86.396.877.8413.2513.6816.8821.1522.4922.67
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Grand Pharmaceutical Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Grand Pharmaceutical Group's financial health and stability.

Assets

Grand Pharmaceutical Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Grand Pharmaceutical Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Grand Pharmaceutical Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Grand Pharmaceutical Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B HKD)DEPRECIATION (M HKD)DEFERRED TAXES (M HKD)CHANGES IN WORKING CAPITAL (M HKD)NON-CASH ITEM (M HKD)PAID INTEREST (M HKD)PAID TAXES (M HKD)NET CASH FLOW FROM OPERATING ACTIVITIES (B HKD)CAPITAL EXPENDITURES (M HKD)CASH FLOW FROM INVESTING ACTIVITIES (M HKD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M HKD)INTEREST INCOME AND EXPENSES (M HKD)NET DEBT CHANGE (B HKD)NET CHANGE IN EQUITY (B HKD)CASH FLOW FROM FINANCING ACTIVITIES (B HKD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M HKD)TOTAL DIVIDENDS PAID (M HKD)NET CHANGE IN CASH FLOW (M HKD)FREE CASH FLOW (M HKD)SHARE-BASED COMPENSATION (M HKD)
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-0.04-0.02-0.12-0.16-0.03-0.09-0.15-0.11-0.01-0.06-0.020.050.160.10.120.130.20.240.310.560.881.362.072.792.52
252125172039427981671129466996171191219243236477287339394
0000000000000000000000000
139-1570-14-711791814-2-36-1565917917-7769-245204-487-487-575-1,242
17043113-2028915-1232693222483838514217116383-41-417-543173
3333332359992726417711114316314917812811592137
000000000002101517172934546594137259277349
0.020.01-0.070.04-0.05-0.03-0.01-0.01-0.01-0.020.030.070.180.010.290.790.480.50.770.721.411.31.462.011.84
-9-13-12-3-10-9-1-1-7-16-17-93-348-796-906-428-479-366-328-377-599-278-536-1,085
40-15-4121-7-43-1305-25-16-464-288-997-979-383-1,595-796-306-4,055-443-1,513-1,768-2,360
49-2-2825-6-312-11212-81-37160-201-7345-1,116-43022-3,677155-1,234-1,232-1,275
0000000000000000000000000
000.040.010.030-0-0.070.020.03-0.02-0.020.080.370.690.20.221.22-0.38-0.15-0.24-0.290.220.360.91
000000.030.030.0800000.3600.010000.3803.430.11.01-0.14-0.04
000.040.010.030.010.020.010.020.02-0.02-0.030.510.340.660.120.111.32-0.06-0.292.96-0.710.77-0.330.33
00005-15-31-2-6-2-873-29-44-72-11696-64-137-220-231-131-158-145
000000000000000000000-290-324-390-390
61-8-6668-20-2612-8117-242224636-38-54198206-169156271147777-83-308
11.3-6.7-82.335-46.7-34.7-23.4-7.7-7.4-24.211.349.591.1-337.2-503.8-114.348.5916.89408.61390.751,030.98704.571,177.351,469.31757.6
0000000000000000000000000

Grand Pharmaceutical Group stock margins

The Grand Pharmaceutical Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Grand Pharmaceutical Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Grand Pharmaceutical Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Grand Pharmaceutical Group's sales revenue. A higher gross margin percentage indicates that the Grand Pharmaceutical Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Grand Pharmaceutical Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Grand Pharmaceutical Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Grand Pharmaceutical Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Grand Pharmaceutical Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Grand Pharmaceutical Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Grand Pharmaceutical Group Margin History

Grand Pharmaceutical Group Gross marginGrand Pharmaceutical Group Profit marginGrand Pharmaceutical Group EBIT marginGrand Pharmaceutical Group Profit margin
2030e61.96 %0 %0 %
2029e61.96 %19.07 %0 %
2028e61.96 %20.24 %0 %
2027e61.96 %21.44 %0 %
2026e61.96 %20.57 %16.33 %
2025e61.96 %20.25 %15.74 %
2024e61.96 %21.07 %15.71 %
202361.96 %27.15 %17.85 %
202262.24 %28.72 %21.75 %
202161.03 %25.37 %27.94 %
202063.52 %28.07 %28.22 %
201961.32 %20.33 %17.46 %
201853.06 %16.13 %11.96 %
201751.97 %14.52 %9.66 %
201646.87 %12.37 %7.28 %
201541.61 %10.92 %5.57 %
201438.23 %9.57 %5.61 %
201333.35 %7.1 %3.75 %
201231.33 %7.15 %3.27 %
201131.26 %7.05 %3.29 %
201035.53 %17.06 %9.29 %
200945.86 %9.68 %5.19 %
200840.64 %-0.78 %-8.97 %
200746.33 %-92.86 %-106.12 %
200644.81 %-16.04 %-25.24 %
200543.32 %-220.47 %-209.48 %
200432.59 %-222.15 %-206.01 %

Grand Pharmaceutical Group Stock Sales Revenue, EBIT, Earnings per Share

The Grand Pharmaceutical Group earnings per share therefore indicates how much revenue Grand Pharmaceutical Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Grand Pharmaceutical Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Grand Pharmaceutical Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Grand Pharmaceutical Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Grand Pharmaceutical Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Grand Pharmaceutical Group Revenue, EBIT and net profit per share

DateGrand Pharmaceutical Group Sales per ShareGrand Pharmaceutical Group EBIT per shareGrand Pharmaceutical Group Earnings per Share
2030e4.01 HKD0 HKD0 HKD
2029e3.97 HKD0 HKD0 HKD
2028e3.84 HKD0 HKD0 HKD
2027e3.69 HKD0 HKD0 HKD
2026e4.39 HKD0 HKD0.72 HKD
2025e3.99 HKD0 HKD0.63 HKD
2024e3.54 HKD0 HKD0.56 HKD
20233 HKD0.81 HKD0.54 HKD
20222.7 HKD0.78 HKD0.59 HKD
20212.42 HKD0.61 HKD0.68 HKD
20201.84 HKD0.52 HKD0.52 HKD
20191.95 HKD0.4 HKD0.34 HKD
20182.13 HKD0.34 HKD0.26 HKD
20171.91 HKD0.28 HKD0.18 HKD
20161.59 HKD0.2 HKD0.12 HKD
20151.46 HKD0.16 HKD0.08 HKD
20141.54 HKD0.15 HKD0.09 HKD
20131.35 HKD0.1 HKD0.05 HKD
20121.05 HKD0.08 HKD0.03 HKD
20110.85 HKD0.06 HKD0.03 HKD
20100.7 HKD0.12 HKD0.06 HKD
20090.41 HKD0.04 HKD0.02 HKD
20080.24 HKD-0 HKD-0.02 HKD
20070.04 HKD-0.04 HKD-0.05 HKD
20060.04 HKD-0.01 HKD-0.01 HKD
20050.05 HKD-0.11 HKD-0.1 HKD
20040.17 HKD-0.38 HKD-0.35 HKD

Grand Pharmaceutical Group business model

China Grand Pharmaceutical and Healthcare Holdings Ltd is an innovative company in the healthcare and pharmaceutical industry in China. The company was founded in 1997 and is headquartered in Wuhan, Hubei Province. China Grand Pharma specializes in developing, manufacturing, and distributing high-quality medications, medical devices, and services. The company has multiple subsidiaries involved in various areas of the healthcare and pharmaceutical industry. China Grand Pharma’s main business areas include the production and sale of synthetic drugs, traditional Chinese medicines, biopharmaceuticals, veterinary medicine, and medical devices and equipment. The company has a high level of technological expertise in synthetic drug development and has a team of experienced scientists and researchers. China Grand Pharma has continuously invested in research and development to develop innovative and effective medications that meet the needs of patients in China and worldwide. The traditional Chinese medicine segment is another important area of China Grand Pharma’s business. The company holds a leading position in the market and offers a wide range of products made from natural plant extracts and traditional Chinese medicines. Biopharmaceuticals, based on innovative technologies such as recombinant DNA technology or stem cell research, are another important focus of China Grand Pharma. The company is able to develop and manufacture high-quality biopharmaceuticals that can be used for the prevention and treatment of serious diseases. China Grand Pharma is also a major player in the veterinary medicine market and offers a wide range of products for the health of livestock and pets. The company has a high level of technological expertise and has an extensive portfolio of products for the diagnosis, prevention, and treatment of animal diseases. The company also offers a wide range of medical devices and equipment for healthcare in hospitals and clinics. China Grand Pharma provides a variety of products, from diagnostic instruments to surgical tools. Overall, China Grand Pharmaceutical and Healthcare Holdings Ltd is one of the leading companies in the healthcare and pharmaceutical industry in China. The company has a comprehensive range of products and is able to provide high-quality products and services for a variety of applications and needs. China Grand Pharma is highly committed to researching and developing medications and technologies that can improve healthcare in China and enhance the lives of patients worldwide. The company has a strong presence in the Chinese market and has a well-established distribution infrastructure that allows it to distribute its products and services in China and beyond. Grand Pharmaceutical Group is one of the most popular companies on Eulerpool.com.

Grand Pharmaceutical Group SWOT Analysis

Strengths

China Grand Pharmaceutical and Healthcare Holdings Ltd holds a strong position in the pharmaceutical and healthcare industry in China. With its extensive product portfolio and well-established distribution network, the company has gained a significant market share.

The company heavily invests in research and development, which allows it to continuously innovate and develop new drugs and healthcare solutions. This helps China Grand Pharmaceutical and Healthcare Holdings Ltd stay ahead of its competitors and offer cutting-edge products.

The company offers a wide range of pharmaceutical products, including prescription drugs, over-the-counter medications, and healthcare devices. This diversification in product offerings enables China Grand Pharmaceutical and Healthcare Holdings Ltd to cater to various customer needs and capture a larger market share.

Weaknesses

China Grand Pharmaceutical and Healthcare Holdings Ltd heavily relies on the domestic Chinese market for its revenue. This concentration exposes the company to risks associated with changes in government regulations, market fluctuations, and economic conditions within China.

The company has a relatively limited international presence compared to some of its global competitors. This restricts its access to overseas markets and potential growth opportunities beyond China.

While China Grand Pharmaceutical and Healthcare Holdings Ltd is well-known within the Chinese market, it still faces challenges in achieving strong brand recognition on a global scale. Building a reputable brand presence internationally may require additional investments and marketing efforts.

Opportunities

China's healthcare market is experiencing rapid growth due to an aging population, increasing disposable income, and government initiatives to enhance healthcare infrastructure. China Grand Pharmaceutical and Healthcare Holdings Ltd can capitalize on this favorable market environment to expand its business and increase sales.

The company has the potential to expand its operations beyond China and tap into the global pharmaceutical and healthcare markets. Strategic partnerships, acquisitions, and investments in research collaborations could help China Grand Pharmaceutical and Healthcare Holdings Ltd establish a stronger international presence.

Advancements in technology, such as digital health solutions, can provide opportunities for China Grand Pharmaceutical and Healthcare Holdings Ltd to develop innovative products and services that cater to the evolving needs of healthcare consumers.

Threats

The pharmaceutical and healthcare industry is highly competitive, both domestically and internationally. China Grand Pharmaceutical and Healthcare Holdings Ltd faces competition from both established players and emerging companies, which can impact its market share and profitability.

Government regulations and policies relating to pharmaceuticals and healthcare can change frequently, posing risks and uncertainties for China Grand Pharmaceutical and Healthcare Holdings Ltd. Compliance with evolving regulations and potential policy shifts can impact the company's operations and financial performance.

The healthcare industry is subject to pricing pressure, driven by factors such as government cost containment efforts, increasing generic competition, and negotiations with healthcare payers. China Grand Pharmaceutical and Healthcare Holdings Ltd must carefully manage pricing strategies to maintain profitability in this challenging market environment.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Grand Pharmaceutical Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Grand Pharmaceutical Group historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Grand Pharmaceutical Group shares outstanding

The number of shares was Grand Pharmaceutical Group in 2024 — This indicates how many shares 3.508 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Grand Pharmaceutical Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Grand Pharmaceutical Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Grand Pharmaceutical Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Grand Pharmaceutical Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Grand Pharmaceutical Group stock splits

In Grand Pharmaceutical Group's history, there have been no stock splits.

Grand Pharmaceutical Group dividend history and estimates

In 2024, Grand Pharmaceutical Group paid a dividend amounting to 0.26 HKD. Dividend means that Grand Pharmaceutical Group distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Grand Pharmaceutical Group provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Grand Pharmaceutical Group’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Grand Pharmaceutical Group's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Grand Pharmaceutical Group Dividend History

DateGrand Pharmaceutical Group Dividend
2030e0.16 HKD
2029e0.16 HKD
2028e0.16 HKD
2027e0.16 HKD
2026e0.16 HKD
2025e0.16 HKD
2024e0.16 HKD
20230.14 HKD
20220.11 HKD
20210.11 HKD
20200.1 HKD
20190.09 HKD

Grand Pharmaceutical Group dividend payout ratio

In 2024, Grand Pharmaceutical Group had a payout ratio of 17.6%. The payout ratio indicates the percentage of the company's profits that Grand Pharmaceutical Group distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Grand Pharmaceutical Group represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Grand Pharmaceutical Group could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Grand Pharmaceutical Group's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Grand Pharmaceutical Group Payout Ratio History

DateGrand Pharmaceutical Group Payout ratio
2030e17.86 %
2029e17.85 %
2028e17.9 %
2027e17.82 %
2026e17.82 %
2025e18.05 %
2024e17.6 %
202317.81 %
202218.74 %
202116.24 %
202018.45 %
201924.98 %
201817.81 %
201717.81 %
201617.81 %
201517.81 %
201417.81 %
201317.81 %
201217.81 %
201117.81 %
201017.81 %
200917.81 %
200817.81 %
200717.81 %
200617.81 %
200517.81 %
200417.81 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Grand Pharmaceutical Group.

Grand Pharmaceutical Group shareholders

%
Name
Stocks
Change
Date
47.09503 % Outwit Investments Ltd1,671,671,149012/31/2023
10.04764 % CDH Investments356,648,142012/31/2023
8.05842 % Shanghai China Grand Asset Finance Investment Management Co Ltd286,039,153012/31/2023
2.80144 % GL Trade Investment Ltd.99,438,959012/31/2023
2.24633 % GL China Long Equity Opportunities Fund SPV, L.P.79,735,000012/31/2023
1.18237 % The Vanguard Group, Inc.41,968,893-177,0009/30/2024
1.16972 % Chau (Tung)41,520,000012/31/2023
0.71934 % Bosera Asset Management Co., Ltd.25,533,500-84,5006/30/2024
0.62043 % Dimensional Fund Advisors, L.P.22,022,50009/30/2024
0.61534 % GF Fund Management Co., Ltd.21,842,000505,5006/30/2024
1
2
3
4
5
...
9

Grand Pharmaceutical Group Executives and Management Board

Dr. Weikun Tang

(37)
Grand Pharmaceutical Group Executive Chairman of the Board; President of Grand Pharma, China (since 2021)
Compensation 1.1 M HKD

Dr. Lin Shi

(58)
Grand Pharmaceutical Group Executive Director
Compensation 661,000 HKD

Ms. Tosi Wan So

(59)
Grand Pharmaceutical Group Independent Non-Executive Director
Compensation 180,000 HKD

Mr. Yebi Hu

(60)
Grand Pharmaceutical Group Independent Non-Executive Director
Compensation 100,000 HKD

Dr. Geng Pei

(62)
Grand Pharmaceutical Group Independent Non-Executive Director
Compensation 60,000 HKD
1
2

Grand Pharmaceutical Group Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Glenmark Pharmaceuticals Stock
Glenmark Pharmaceuticals
SupplierCustomer0,830,830,250,650,760,48
Telix Pharmaceuticals Stock
Telix Pharmaceuticals
SupplierCustomer0,660,520,510,700,10-0,10
Biohit B Stock
Biohit B
SupplierCustomer0,530,880,660,730,670,22
Huadong Medicine A Stock
Huadong Medicine A
SupplierCustomer0,250,290,720,640,740,26
OncoSec Medical Stock
OncoSec Medical
SupplierCustomer0,140,840,170,230,730,37
1

Most common questions regarding Grand Pharmaceutical Group

What values and corporate philosophy does Grand Pharmaceutical Group represent?

China Grand Pharmaceutical and Healthcare Holdings Ltd represents a commitment to providing high-quality healthcare products and services. With a strong emphasis on innovation and research, the company strives to develop effective and safe medicines that contribute to the well-being of individuals. China Grand Pharmaceutical and Healthcare Holdings Ltd also values integrity, transparency, and social responsibility in its business practices. By adhering to these values and corporate philosophy, the company aims to enhance healthcare accessibility and improve the overall quality of life for people in China and beyond.

In which countries and regions is Grand Pharmaceutical Group primarily present?

China Grand Pharmaceutical and Healthcare Holdings Ltd is primarily present in China.

What significant milestones has the company Grand Pharmaceutical Group achieved?

China Grand Pharmaceutical and Healthcare Holdings Ltd, a leading healthcare company, has achieved significant milestones in its journey. Over the years, the company has expanded its presence and made remarkable strides. It has successfully developed and launched various innovative healthcare products, contributing to the improvement of global healthcare standards. China Grand Pharmaceutical and Healthcare Holdings Ltd has received numerous accolades and recognition for its outstanding research and development efforts, quality management, and commitment to patient care. With a strong focus on continuous innovation and growth, the company continues to establish itself as a key player in the pharmaceutical and healthcare industry.

What is the history and background of the company Grand Pharmaceutical Group?

China Grand Pharmaceutical and Healthcare Holdings Ltd is a leading pharmaceutical company in China. Established in 2000, the company has a rich history and extensive experience in the healthcare industry. It specializes in the research, development, manufacturing, and sale of a wide range of pharmaceutical products and healthcare services. With a dedication to innovation and quality, China Grand Pharmaceutical has become a trusted name in the industry. The company focuses on enhancing medical advancements, improving patient well-being, and contributing to the overall development of the pharmaceutical sector in China. China Grand Pharmaceutical continues to grow and expand its portfolio, serving as a driving force in the healthcare industry.

Who are the main competitors of Grand Pharmaceutical Group in the market?

The main competitors of China Grand Pharmaceutical and Healthcare Holdings Ltd in the market include Sinopharm Group Co Ltd, Shanghai Fosun Pharmaceutical Group Co Ltd, and Sino Biopharmaceutical Limited.

In which industries is Grand Pharmaceutical Group primarily active?

China Grand Pharmaceutical and Healthcare Holdings Ltd is primarily active in the pharmaceutical and healthcare industries.

What is the business model of Grand Pharmaceutical Group?

The business model of China Grand Pharmaceutical and Healthcare Holdings Ltd. revolves around its diverse healthcare portfolio. As a leading pharmaceutical company based in China, it engages in the research, development, production, and distribution of a wide range of pharmaceutical products and medical devices. The company's core focus lies in the fields of innovative drug discovery, modernized traditional Chinese medicine, and the provision of high-quality medical services. With a dedication to improving healthcare outcomes, China Grand Pharmaceutical and Healthcare Holdings Ltd. aims to meet the evolving needs of patients and healthcare professionals, while contributing to the advancement of the healthcare industry.

What is the P/E ratio of Grand Pharmaceutical Group 2025?

The Grand Pharmaceutical Group P/E ratio is 7.55.

What is the P/S ratio of Grand Pharmaceutical Group 2025?

The Grand Pharmaceutical Group P/S ratio is 1.19.

What is the Quality Investing of Grand Pharmaceutical Group?

The Quality Investing for Grand Pharmaceutical Group is 9/10.

What is the revenue of Grand Pharmaceutical Group 2025?

The expected Grand Pharmaceutical Group revenue is 14.16 B HKD.

How high is the profit of Grand Pharmaceutical Group 2025?

The expected Grand Pharmaceutical Group profit is 2.23 B HKD.

What is the business model of Grand Pharmaceutical Group

China Grand Pharmaceutical and Healthcare Holdings Ltd is a leading company in the Chinese biotechnology and pharmaceutical industry. It offers a variety of products and services, including medications, health products, and medical devices. The core business areas of China Grand include research and development, production and marketing of medications, health products, and medical devices, as well as operating clinics and hospitals. China Grand's research and development department focuses on discovering, developing, and marketing innovative medications for diseases such as cancer, diabetes, cardiovascular diseases, and infectious diseases. The company has become a major player in the Chinese biotechnology industry through extensive investments and strategic partnerships. In addition to developing its own medications, China Grand has also acquired licenses for marketing foreign medications. The company provides its customers with a wide range of medications that meet the highest quality and safety standards. China Grand's health product division offers a wide range of products aimed at promoting the health and well-being of customers. These include dietary supplements, vitamins, herbal extracts, traditional Chinese medicine products, and cosmetic products. These products are sold both online and through a broad distribution channel in pharmacies and drugstores. China Grand's medical devices division produces a wide range of devices and instruments used by clinics, hospitals, and other medical facilities for diagnosing and treating diseases. These include ultrasound devices, X-ray machines, CT scanners, magnetic resonance imaging machines, and other medical devices. In addition to its product lines, China Grand also operates a number of its own clinics and hospitals that offer a wide range of medical services. China Grand's clinics are known for their modern facilities, state-of-the-art medical equipment, and excellent staff. Overall, China Grand Pharmaceutical and Healthcare Holdings Ltd offers a wide range of products and services that meet the needs of customers throughout the Chinese healthcare industry. The company is well positioned to benefit from the strong growth in the Chinese healthcare industry and further expand its leading role in the industry.

What is the Grand Pharmaceutical Group dividend?

Grand Pharmaceutical Group pays a dividend of 0.11 HKD distributed over payouts per year.

How often does Grand Pharmaceutical Group pay dividends?

The dividend cannot currently be calculated for Grand Pharmaceutical Group or the company does not pay out a dividend.

What is the Grand Pharmaceutical Group ISIN?

The ISIN of Grand Pharmaceutical Group is BMG210A71016.

What is the Grand Pharmaceutical Group WKN?

The WKN of Grand Pharmaceutical Group is A0Q8LD.

What is the Grand Pharmaceutical Group ticker?

The ticker of Grand Pharmaceutical Group is 512.HK.

How much dividend does Grand Pharmaceutical Group pay?

Over the past 12 months, Grand Pharmaceutical Group paid a dividend of 0.14 HKD . This corresponds to a dividend yield of about 2.92 %. For the coming 12 months, Grand Pharmaceutical Group is expected to pay a dividend of 0.16 HKD.

What is the dividend yield of Grand Pharmaceutical Group?

The current dividend yield of Grand Pharmaceutical Group is 2.92 %.

When does Grand Pharmaceutical Group pay dividends?

Grand Pharmaceutical Group pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Grand Pharmaceutical Group?

Grand Pharmaceutical Group paid dividends every year for the past 0 years.

What is the dividend of Grand Pharmaceutical Group?

For the upcoming 12 months, dividends amounting to 0.16 HKD are expected. This corresponds to a dividend yield of 3.27 %.

In which sector is Grand Pharmaceutical Group located?

Grand Pharmaceutical Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Grand Pharmaceutical Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Grand Pharmaceutical Group from 6/27/2024 amounting to 0.26 HKD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did Grand Pharmaceutical Group pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Grand Pharmaceutical Group in the year 2024?

In the year 2024, Grand Pharmaceutical Group distributed 0.14 HKD as dividends.

In which currency does Grand Pharmaceutical Group pay out the dividend?

The dividends of Grand Pharmaceutical Group are distributed in HKD.

All fundamentals about Grand Pharmaceutical Group

Our stock analysis for Grand Pharmaceutical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Grand Pharmaceutical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.